Ellence Injection, Solution
Product Images NDC 0009-5091

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Ellence (NDC 0009-5091). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ellence 01)

A line graph depicting the probability on the vertical axis against cumulative epirubicin dose (mg/m2) on the horizontal axis, showing an increasing trend in probability with higher doses.*

FDA Label Image

Figure 2 (Ellence 02)

A line graph showing the probability on the y-axis versus cumulative epirubicin dose (mg/m²) on the x-axis. The curve rises gradually at lower doses and increases steeply as the dose approaches 1000 mg/m², indicating a dose-dependent relationship for epirubicin hydrochloride.*

FDA Label Image

Chemical Structure (Ellence 03)

Chemical structure diagram of epirubicin hydrochloride showing its molecular arrangement including hydroxyl, carbonyl, methoxy, and amino groups.*

FDA Label Image

Figure 3 (Ellence 04)

A Kaplan-Meier curve chart illustrating relapse-free survival probabilities over a 10-year period for Epirubicin treatment (CTN 068103-999). The chart compares two treatment groups, CEF and CMF, showing survival probability on the y-axis and years on the x-axis for the ITT population. The solid line represents CEF, and the dashed line represents CMF.*

FDA Label Image

Figure 4 (Ellence 05)

A Kaplan-Meier survival curve chart showing overall survival probability over 10 years from a study involving epirubicin treatment. The plot compares two treatment groups, labeled CEF and CMF, with probability on the vertical axis and years on the horizontal axis. The chart illustrates survival trends in an intent-to-treat (ITT) population.*

FDA Label Image

Figure 5 (Ellence 06)

A Kaplan-Meier curve graph titled 'Epirubicin GFEA 05 10-years FU Relapse-Free Survival Kaplan-Meier Curves by Treatment (ITT Population).' The graph plots probability on the y-axis against years on the x-axis up to 12 years, comparing two treatment groups labeled FEC 50 (solid line) and FEC 100 (dashed line). The curves depict relapse-free survival over time.*

FDA Label Image

Figure 6 (Ellence 07)

Kaplan-Meier survival curves graph depicting overall survival probability over 12 years for patients treated with epirubicin. Two treatment groups, labeled FEC 50 and FEC 100, are compared, showing probability on the vertical axis and years on the horizontal axis. The solid line represents FEC 50 and the dashed line represents FEC 100.*

FDA Label Image

Logo (Ellence 08)

FDA Label Image

Principal Display Panel (50 mg/25 mL Vial Label)

Label for Ellence 50 mg/25 mL injection (epirubicin hydrochloride) at 2 mg/mL strength. This single-dose vial is for intravenous use only and is distributed by Pharmacia & Upjohn Company LLC. The label includes storage instructions to keep refrigerated between 2°C to 8°C and protect from light, with no preservatives in the solution. The label features the Pfizer Injectables logo and mentions the product is made in Australia.*

FDA Label Image

Principal Display Panel (50 mg/25 mL Vial Carton)

Packaging label for Ellence 50 mg/25 mL (2 mg/mL) injection, an epirubicin hydrochloride intravenous solution. The label indicates it is a single-dose vial, distributed by Pharmacia & Upjohn Company LLC, a division of Pfizer Inc, made in Australia. Warnings include cytotoxic agent caution, refrigerated storage between 2°C to 8°C, and protection from light. The label highlights no preservatives, dosage instructions refer to accompanying prescribing information, and the solution pH is adjusted to 3.0.*

FDA Label Image

Principal Display Panel (200 mg/100 mL Vial Label)

Label for Ellence injection with epirubicin hydrochloride at 2 mg/mL (200 mg/100 mL) strength in a single-dose vial. The label indicates intravenous use only and includes storage instructions (refrigerate between 2°C to 8°C, do not freeze, protect from light). Distributed by Pharmacia & Upjohn Company LLC, a division of Pfizer Inc., made in Australia.*

FDA Label Image

Principal Display Panel (200 mg/100 mL Vial Carton)

Packaging label for Ellence injection, solution, containing epirubicin hydrochloride at 200 mg/100 mL (2 mg/mL) strength. The label states single-dose vial for intravenous use only. Distributed by Pharmacia & Upjohn Company LLC, division of Pfizer Inc. Includes storage instructions and cytotoxic agent caution. Made in Australia.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.